131I-Sibrotuzumab

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug Name131I-Sibrotuzumab
Drug Alias Nameiodine I 131 monoclonal antibody F19Sibrotuzumab I-131Sibrotuzumab conjugated with 131I131I-BIBH-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Iodine > 131IRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionFibroblast activation protein alpha antagonists
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International GmbhLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A